An interleukin (IL-4/IL-13) inhibitor biologic
Dupilumab
An injected biologic that blocks the IL-4 and IL-13 allergic signals, used for moderate to severe eczema and asthma.
What is Dupilumab?
Dupilumab is a biologic medicine that calms the allergic, inflammatory part of the immune system by blocking two messenger proteins, interleukin-4 and interleukin-13. It is used for moderate to severe atopic eczema, certain types of asthma, and some related allergic conditions. It is given by injection under the skin, which many people learn to do themselves. Unlike many other biologics it is not broadly immunosuppressive, so it does not carry the same infection risk; however, it commonly causes eye and conjunctivitis problems and injection-site reactions. Live vaccines are still avoided during treatment.
Education and reference only. This is a plain-language guide to Dupilumab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Dupilumab is a biologic medicine, made from living cells, that targets two closely related immune signals, interleukin-4 and interleukin-13. These messengers drive the type of allergic inflammation behind eczema, asthma and some related conditions. Dupilumab is used for moderate to severe atopic eczema (the most common type of eczema), certain types of asthma that are not controlled by usual treatment, and some other allergic conditions such as chronic nasal inflammation with polyps. It is given by injection under the skin, and many people are trained to give it themselves at home using a pre-filled pen.
How it works
In allergic conditions such as eczema and some asthma, the immune system over-produces signals called interleukin-4 and interleukin-13, which drive itchy, inflamed skin or inflamed, twitchy airways. Dupilumab blocks the shared pathway these two signals use, calming this specific allergic inflammation. Importantly, it acts on this allergic pathway rather than suppressing the immune system broadly, which is why it does not carry the same infection risk as many other biologics. Its most characteristic effect comes from this same pathway: it can cause eye problems such as conjunctivitis.
Company & origin
Originated / developed by: Sanofi and Regeneron.
A biologic medicine developed to treat moderate to severe atopic eczema, asthma and some related allergic conditions by blocking the immune signals IL-4 and IL-13.
What it treats
Conditions Dupilumab is used for
Practical use
How to take Dupilumab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given by injection under the skin, often with a pre-filled pen that many people learn to use themselves at home.
- Tell your team if your eyes become red, sore, gritty or itchy, as conjunctivitis is a common effect that can usually be treated.
- Expect some injection-site redness or soreness; rotating where you inject can help.
- Avoid live vaccines while being treated, even though it does not suppress the immune system broadly; your team can advise on other vaccines.
- Keep using your other prescribed treatments, such as asthma inhalers or eczema creams, unless your team tells you otherwise.
Weighing it up
Advantages & disadvantages of Dupilumab
Advantages
- Often very effective at reducing itch and clearing the skin in moderate to severe eczema, and at cutting asthma attacks.
- Not broadly immunosuppressive, so it does not carry the same infection risk as many other biologics.
- Can usually be self-injected at home after training, with doses spaced weeks apart once established.
Disadvantages
- Commonly causes eye problems such as conjunctivitis, with red, sore or gritty eyes.
- Injection-site reactions such as redness and soreness are common.
- It is a biologic given by injection, and live vaccines are still avoided during treatment.
Practical use
Good to know
A key point is that dupilumab is not broadly immunosuppressive; it targets the allergic IL-4 and IL-13 pathway, so it does not carry the same infection risk as many other biologics. Even so, as with any biologic, live vaccines are avoided during treatment. The most characteristic side effect is eye and eyelid problems, especially conjunctivitis (red, sore, gritty or itchy eyes), which is common; tell your team if your eyes become irritated, as it can usually be managed. Injection-site reactions such as redness or soreness are also common. After training, most people give the injections themselves at home, with doses spaced weeks apart once established. In eczema it often greatly reduces itch and improves the skin, and in asthma it can cut down attacks.
Who should not take it / use with caution
- It is not suitable for treating a sudden asthma attack; it is a preventive treatment, not a reliever.
- People with an existing eye condition should tell their team, as eye side effects are common and may need monitoring.
- Live vaccines should be avoided during treatment, so this needs planning around any immunisations.
Monitoring
- Watching for eye symptoms such as conjunctivitis so they can be treated promptly.
- Reviewing how well the skin or asthma is responding so treatment and other medicines can be adjusted.
- Checking vaccination status and planning any immunisations around the treatment.
Side effects
- Eye and eyelid problems, especially conjunctivitis (red, sore, gritty or itchy eyes), are the most characteristic effect.
- Redness or soreness where the injection is given is common and usually mild.
- Cold sores or, rarely, allergic reactions; a sudden severe reaction needs urgent medical attention.
Key interactions
- It is not broadly immunosuppressive, but live vaccines are still avoided during treatment.
- It is usually used alongside your existing eczema or asthma treatments rather than replacing them.
- Tell your team about all your medicines, as starting it can sometimes allow other treatments to be reduced over time.
Available as: Injection under the skin, often with a pre-filled pen for self-injection after training.
Answers
Dupilumab: frequently asked questions
Does dupilumab weaken my immune system?
It is not broadly immunosuppressive; it blocks the allergic IL-4 and IL-13 pathway rather than suppressing the immune system widely, so it does not carry the same infection risk as many other biologics.
Why are my eyes sore since starting it?
Eye problems such as conjunctivitis are the most characteristic effect of dupilumab; tell your team, as red, sore or gritty eyes can usually be treated.
Can it stop an asthma attack?
No, it is a preventive treatment that reduces attacks over time, not a reliever; keep your reliever inhaler for sudden symptoms.
Can I have vaccinations during treatment?
Live vaccines are avoided while you are being treated; your team can advise on other vaccines and on timing.
How is it given?
It is given by injection under the skin, and many people learn to inject it themselves at home with a pre-filled pen, with doses spaced weeks apart.
The wider class
About Interleukin (IL-4/IL-13) inhibitor biologic
Dupilumab belongs to the interleukin (il-4/il-13) inhibitor biologic class. For how the class as a whole works, its shared safety principles and monitoring, see the full guide.
Browse by body system
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.